Albumin-Modified Gold Nanoparticles as Novel Radiosensitizers for Enhancing Lung Cancer Radiotherapy
Yao Chen,Shuya Liu,Yin Liao,Hanshan Yang,Zhuo Chen,Yuru Hu,Shaozhi Fu,Jingbo Wu
DOI: https://doi.org/10.2147/IJN.S398254
IF: 7.033
2023-04-12
International Journal of Nanomedicine
Abstract:Yao Chen, 1, &ast Shuya Liu, 1, &ast Yin Liao, 1, &ast Hanshan Yang, 1 Zhuo Chen, 1 Yuru Hu, 1 Shaozhi Fu, 1 Jingbo Wu 1– 3 1 Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China; 2 Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, People's Republic of China; 3 Academician (Expert) Workstation of Sichuan Province, Luzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Shaozhi Fu; Jingbo Wu, Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, 646000, People's Republic of China, Tel/Fax +86 8303165696, Email ; Background: Considering the strong attenuation of photons and the potential to increase the deposition of radiation, high-atomic number nanomaterials are often used as radiosensitizers in cancer radiotherapy, of which gold nanoparticles (GNPs) are widely used. Materials and Methods: We prepared albumin-modified GNPs (Alb-GNPs) and observed their radiosensitizing effects and biotoxicity in human non-small-cell lung carcinoma tumor-bearing mice models. Results: The prepared nanoparticles (Alb-GNPs) demonstrated excellent colloidal stability and biocompatibility at the mean size of 205.06 ± 1.03 nm. Furthermore, clone formation experiments revealed that Alb-GNPs exerted excellent radiosensitization, with a sensitization enhancement ratio (SER) of 1.432, which is higher than X-ray alone. Our in vitro and in vivo data suggested that Alb-GNPs enabled favorable accumulation in tumors, and the combination of Alb-GNPs and radiotherapy exhibited a relatively greater radiosensitizing effect and anti-tumor activity. In addition, no toxicity or abnormal irritating response resulted from the application of Alb-GNPs. Conclusion: Alb-GNPs can be used as an effective radiosensitizer to improve the efficacy of radiotherapy with minimal damage to healthy tissues. Keywords: albumin, gold nanoparticles, radiosensitization, lung cancer, radiotherapy According to the latest global cancer burden data released by the International Cancer Research Agency (ICRA) of the World Health Organization in 2022, lung cancer is the second most malignant tumor for humans, responsible for approximately one-fourth of all cancer-related fatalities, making it a serious threat to the human health and quality of life. 1 Although the available lung cancer treatment tends to be diversified and precise, the treatment effect is not satisfactory. Radiotherapy refers to the use of high-energy ionizing radiation to induce lethal damage to cancer cells, which is critical in the treatment of primary and metastatic solid tumors as well as in inhibiting the metastasis of microscopic tumor and regional lymph nodes. Therefore, radiotherapy is usually applied as one of the primary lung cancer treatments. About 77% of lung cancer patients have evidence-based indications for radiotherapy. 2 In the course of radiotherapy, the maximum amount of radiotherapy must be delivered to the tumor site whenever possible while avoiding damage to normal and healthy tissues, and ultimately improving the treatment outcome. Presently, radiotherapy has entered the era of precision and intelligent therapy, such as application under the guidance of PET and magnetic resonance imaging (MRI) for precise tumor targeting/location and the use of linear accelerators and three-dimensional treatment plans, including stereotactic radiotherapy, intensity-modulated radiation therapy, and the use of charged particles in radiotherapy; these interventions have improved the overall efficacy of radiotherapy. 3 However, the side effects of radiotherapy, including uneven local dose distribution, radiation pneumonitis, myelosuppression after radiotherapy, limited tolerance of normal tissues to high-energy rays, increased tumor resistance to radiotherapy, respiratory mobility, lung infection, and others, significantly limit its application. Interestingly, radiosensitizers seem to be a good choice to improve radiosensitivity. Currently, a variety of radiosensitizers (such as cisplatin, nitroimidazole, epoxygenase-2 inhibitors, and iodinated DNA targeting agents) have been developed and being applied to tumor radiotherapy. The ideal radiosensitizer should not only enhance the radiotherapy effect of the tumor but also have low toxicity or be non-toxic to the normal tissues, as well as protect the normal tissues. 4 Presently, only a few efficient, non-toxic, low cost, and radiosensitizing materials are available for clinical -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology